Man­u­fac­tur­ing roundup: Mus­tang Bio clos­es sale with uBri­Gene; In­di­an syrup man­u­fac­tur­er halts pro­duc­tion af­ter gov­ern­ment or­der

Mus­tang Bio has both amend­ed and closed the agree­ment with CD­MO uBri­Gene, to sell Mus­tang’s man­u­fac­tur­ing fa­cil­i­ty.

The new agree­ment will see uBri­Gene ac­quir­ing all of Mus­tang’s as­sets re­lat­ed to man­u­fac­tur­ing cell and gene ther­a­pies for $6 mil­lion up­front in cash. Ac­cord­ing to a re­lease, the lease to Mus­tang’s 27,000-square-foot fa­cil­i­ty in Worces­ter, MA, is not yet a part of the deal be­cause the land­lord is tak­ing more time to con­sid­er the trans­fer. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER